Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(9-10):1413–1418. doi: 10.1038/sj.bjc.6690226

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer

K J O'Byrne 1, N Dobbs 1, D J Propper 1, J P Braybrooke 1, M I Koukourakis 1, K Mitchell 1, J Woodhull 1, D C Talbot 1, A V Schally 2, A L Harris 1
PMCID: PMC2362707  PMID: 10188884

Abstract

RC-160 (octastatin/vapreotide) is a potent octapeptide analogue of somatostatin with growth inhibitory activity in experimental tumours in vitro and in vivo, including breast cancer. We evaluated the efficacy and tolerability of high-dose RC-160, 3 mg day−1 on week 1 increased to 4.5 mg day−1 for weeks 2–4 and subsequently 6 mg day−1 until the end of treatment, administered by continuous subcutaneous infusion in the management of 14 women with previously treated metastatic breast cancer. The age range was 37–80 years (median 58.5 years) and performance status 0–2. The treatment was well tolerated with no dose reductions being required. No grade 3 or 4 toxicities were seen. Abscess formation developed at the infusion site in eight patients and erythema and discomfort was seen in a further three patients. A significant reduction in IGF-I levels occurred by day 7 and was maintained throughout the treatment. The lowest dose of RC-160 produced the maximal IGF-I response. Although there was no reduction in prolactin levels in patients whose baseline levels were normal, elevated prolactin levels found in three patients fell to within the normal range 7 days after commencing RC-160 treatment. A small but significant rise in fasting blood glucose levels was also recorded, the highest level on treatment being 7.6 mmol l−1. No objective tumour responses were observed, all patients showing disease progression within 3 months of commencing treatment. These findings demonstrate that high-dose RC-160, administered as a continuous subcutaneous infusion, can reduce serum levels of the breast growth factors IGF-I and prolactin but is ineffective in the management of metastatic breast cancer. Encouraging preclinical anti-tumour activity and the favourable toxicity profile in patients suggest the merit of future studies combining RC-160 with anti-oestrogen, cytotoxic and anti-angiogenic agents. © 1999 Cancer Research Campaign

Keywords: somatostatin, RC-160, breast cancer, metastatic, insulin-like growth factor-I, prolactin

Full Text

The Full Text of this article is available as a PDF (108.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bates P., Fisher R., Ward A., Richardson L., Hill D. J., Graham C. F. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II) Br J Cancer. 1995 Nov;72(5):1189–1193. doi: 10.1038/bjc.1995.484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Battershill P. E., Clissold S. P. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 1989 Nov;38(5):658–702. doi: 10.2165/00003495-198938050-00002. [DOI] [PubMed] [Google Scholar]
  3. Bontenbal M., Foekens J. A., Lamberts S. W., de Jong F. H., van Putten W. L., Braun H. J., Burghouts J. T., van der Linden G. H., Klijn J. G. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br J Cancer. 1998;77(1):115–122. doi: 10.1038/bjc.1998.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brower S. T., Schally A. V., Redding T. W., Hollander V. P. Differential effects of LHRH and somatostatin analogs on human breast cancer. J Surg Res. 1992 Jan;52(1):6–14. doi: 10.1016/0022-4804(92)90271-z. [DOI] [PubMed] [Google Scholar]
  5. Bruns C., Weckbecker G., Raulf F., Kaupmann K., Schoeffter P., Hoyer D., Lübbert H. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci. 1994 Sep 15;733:138–146. doi: 10.1111/j.1749-6632.1994.tb17263.x. [DOI] [PubMed] [Google Scholar]
  6. Buscail L., Delesque N., Estève J. P., Saint-Laurent N., Prats H., Clerc P., Robberecht P., Bell G. I., Liebow C., Schally A. V. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2315–2319. doi: 10.1073/pnas.91.6.2315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Buscail L., Estève J. P., Saint-Laurent N., Bertrand V., Reisine T., O'Carroll A. M., Bell G. I., Schally A. V., Vaysse N., Susini C. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580–1584. doi: 10.1073/pnas.92.5.1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cai R. Z., Szoke B., Lu R., Fu D., Redding T. W., Schally A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1896–1900. doi: 10.1073/pnas.83.6.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Candi E., Melino G., De Laurenzi V., Piacentini M., Guerrieri P., Spinedi A., Knight R. A. Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett. 1995 Sep 4;96(1):141–145. doi: 10.1016/0304-3835(95)03924-l. [DOI] [PubMed] [Google Scholar]
  10. Canobbio L., Cannata D., Miglietta L., Boccardo F. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res. 1995 Nov-Dec;15(6B):2687–2690. [PubMed] [Google Scholar]
  11. Caron P., Morange-Ramos I., Cogne M., Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 1997 Jan;82(1):18–22. doi: 10.1210/jcem.82.1.3714. [DOI] [PubMed] [Google Scholar]
  12. Chan J. M., Stampfer M. J., Giovannucci E., Gann P. H., Ma J., Wilkinson P., Hennekens C. H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998 Jan 23;279(5350):563–566. doi: 10.1126/science.279.5350.563. [DOI] [PubMed] [Google Scholar]
  13. Clevenger C. V., Chang W. P., Ngo W., Pasha T. L., Montone K. T., Tomaszewski J. E. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol. 1995 Mar;146(3):695–705. [PMC free article] [PubMed] [Google Scholar]
  14. Cordelier P., Estève J. P., Bousquet C., Delesque N., O'Carroll A. M., Schally A. V., Vaysse N., Susini C., Buscail L. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9343–9348. doi: 10.1073/pnas.94.17.9343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Das R., Vonderhaar B. K. Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat. 1996;40(2):141–149. doi: 10.1007/BF01806209. [DOI] [PubMed] [Google Scholar]
  16. Di Leo A., Ferrari L., Bajetta E., Bartoli C., Vicario G., Moglia D., Miceli R., Callegari M., Bono A. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology. Breast Cancer Res Treat. 1995 Jun;34(3):237–244. doi: 10.1007/BF00689715. [DOI] [PubMed] [Google Scholar]
  17. Erwin R. A., Kirken R. A., Malabarba M. G., Farrar W. L., Rui H. Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless. Endocrinology. 1995 Aug;136(8):3512–3518. doi: 10.1210/endo.136.8.7628388. [DOI] [PubMed] [Google Scholar]
  18. Evans A. A., Crook T., Laws S. A., Gough A. C., Royle G. T., Primrose J. N. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer. 1997;75(6):798–803. doi: 10.1038/bjc.1997.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995 Dec 28;333(26):1757–1763. doi: 10.1056/NEJM199512283332608. [DOI] [PubMed] [Google Scholar]
  20. Goldhirsch A., Gelber R. D. Endocrine therapies of breast cancer. Semin Oncol. 1996 Aug;23(4):494–505. [PubMed] [Google Scholar]
  21. Hankinson S. E., Willett W. C., Colditz G. A., Hunter D. J., Michaud D. S., Deroo B., Rosner B., Speizer F. E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998 May 9;351(9113):1393–1396. doi: 10.1016/S0140-6736(97)10384-1. [DOI] [PubMed] [Google Scholar]
  22. Hayes D. F., Henderson I. C., Shapiro C. L. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol. 1995 Apr;22(2 Suppl 5):5–21. [PubMed] [Google Scholar]
  23. Helle S. I., Geisler J., Poulsen J. P., Hestdal K., Meadows K., Collins W., Tveit K. M., Holly J. M., Lønning P. E. Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study. Br J Cancer. 1998 Jul;78(1):14–20. doi: 10.1038/bjc.1998.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Helle S. I., Lønning P. E. Insulin-like growth factors in breast cancer. Acta Oncol. 1996;35 (Suppl 5):19–22. doi: 10.3109/02841869609083963. [DOI] [PubMed] [Google Scholar]
  25. Hofland L. J., van Koetsveld P. M., Waaijers M., Zuyderwijk J., Lamberts S. W. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology. 1994 Jan;134(1):301–306. doi: 10.1210/endo.134.1.7903931. [DOI] [PubMed] [Google Scholar]
  26. Holly J. Insulin-like growth factor-I and new opportunities for cancer prevention. Lancet. 1998 May 9;351(9113):1373–1375. doi: 10.1016/S0140-6736(05)79438-1. [DOI] [PubMed] [Google Scholar]
  27. Ingle J. N., Kardinal C. G., Suman V. J., Krook J. E., Hatfield A. K. Octreotide as first-line treatment for women with metastatic breast cancer. Invest New Drugs. 1996;14(2):235–237. doi: 10.1007/BF00210797. [DOI] [PubMed] [Google Scholar]
  28. Klijn J. G., Berns E. M., Foekens J. A. Prognostic factors and response to therapy in breast cancer. Cancer Surv. 1993;18:165–198. [PubMed] [Google Scholar]
  29. Lamberts S. W., Krenning E. P., Reubi J. C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991 Nov;12(4):450–482. doi: 10.1210/edrv-12-4-450. [DOI] [PubMed] [Google Scholar]
  30. Lee J. M., Erlich R. B., Bruckner H. W., Szrajer L., Ohnuma T. A somatostatin analogue (SMS 201-995) alters the toxicity of 5-fluorouracil in Swiss mice. Anticancer Res. 1993 Sep-Oct;13(5A):1453–1456. [PubMed] [Google Scholar]
  31. Macaulay V. M. Insulin-like growth factors and cancer. Br J Cancer. 1992 Mar;65(3):311–320. doi: 10.1038/bjc.1992.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Manni A., Boucher A. E., Demers L. M., Harvey H. A., Lipton A., Simmonds M. A., Bartholomew M. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat. 1989 Dec;14(3):289–298. doi: 10.1007/BF01806300. [DOI] [PubMed] [Google Scholar]
  33. Nagy A., Schally A. V., Halmos G., Armatis P., Cai R. Z., Csernus V., Kovács M., Koppán M., Szepesházi K., Kahán Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1794–1799. doi: 10.1073/pnas.95.4.1794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Patel P. C., Barrie R., Hill N., Landeck S., Kurozawa D., Woltering E. A. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery. 1994 Dec;116(6):1148–1152. [PubMed] [Google Scholar]
  35. Pinski J., Schally A. V., Halmos G., Szepeshazi K., Groot K., O'Byrne K., Cai R. Z. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer. 1994 Nov;70(5):886–892. doi: 10.1038/bjc.1994.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Pinski J., Schally A. V., Halmos G., Szepeshazi K., Groot K. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer. 1996 Mar 15;65(6):870–874. doi: 10.1002/(SICI)1097-0215(19960315)65:6<870::AID-IJC27>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  37. Pollak M. N., Schally A. V. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med. 1998 Feb;217(2):143–152. doi: 10.3181/00379727-217-44216. [DOI] [PubMed] [Google Scholar]
  38. Pollak M. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Digestion. 1996;57 (Suppl 1):29–33. doi: 10.1159/000201389. [DOI] [PubMed] [Google Scholar]
  39. Prévost G., Israel L. Somatostatin and somatostatin analogues in human breast carcinoma. Recent Results Cancer Res. 1993;129:63–70. doi: 10.1007/978-3-642-84956-5_5. [DOI] [PubMed] [Google Scholar]
  40. Qin Y., Ertl T., Groot K., Horvath J., Cai R. Z., Schally A. V. Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate. Int J Cancer. 1995 Mar 3;60(5):694–700. doi: 10.1002/ijc.2910600521. [DOI] [PubMed] [Google Scholar]
  41. Reichlin S. Somatostatin (second of two parts). N Engl J Med. 1983 Dec 22;309(25):1556–1563. doi: 10.1056/NEJM198312223092506. [DOI] [PubMed] [Google Scholar]
  42. Reichlin S. Somatostatin. N Engl J Med. 1983 Dec 15;309(24):1495–1501. doi: 10.1056/NEJM198312153092406. [DOI] [PubMed] [Google Scholar]
  43. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 1988 Dec 15;48(24 Pt 1):6977–6985. [PubMed] [Google Scholar]
  44. Setyono-Han B., Henkelman M. S., Foekens J. A., Klijn G. M. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res. 1987 Mar 15;47(6):1566–1570. [PubMed] [Google Scholar]
  45. Sheshberadaran H., Payne L. G. Protein antigen-monoclonal antibody contact sites investigated by limited proteolysis of monoclonal antibody-bound antigen: protein "footprinting". Proc Natl Acad Sci U S A. 1988 Jan;85(1):1–5. doi: 10.1073/pnas.85.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Srkalovic G., Szende B., Redding T. W., Groot K., Schally A. V. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. Proc Soc Exp Biol Med. 1989 Dec;192(3):209–218. doi: 10.3181/00379727-192-42987. [DOI] [PubMed] [Google Scholar]
  47. Stolfi R., Parisi A. M., Natoli C., Iacobelli S. Advanced breast cancer: response to somatostatin. Anticancer Res. 1990 Jan-Feb;10(1):203–204. [PubMed] [Google Scholar]
  48. Szende B., Lapis K., Redding T. W., Srkalovic G., Schally A. V. Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Res Treat. 1989 Dec;14(3):307–314. doi: 10.1007/BF01806302. [DOI] [PubMed] [Google Scholar]
  49. Szende B., Schally A. V., Lapis K. Immunocytochemical demonstration of tissue transglutaminase indicative of programmed cell death (apoptosis) in hormone sensitive mammary tumours. Acta Morphol Hung. 1991;39(1):53–58. [PubMed] [Google Scholar]
  50. Szepeshazi K., Lapis K., Schally A. V. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Int J Cancer. 1991 Sep 9;49(2):260–266. doi: 10.1002/ijc.2910490220. [DOI] [PubMed] [Google Scholar]
  51. Szepeshazi K., Milovanovic S., Lapis K., Groot K., Schally A. V. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat. 1992;21(3):181–192. doi: 10.1007/BF01975001. [DOI] [PubMed] [Google Scholar]
  52. Teicher B. A., Holden S. A., Ara G., Sotomayor E. A., Huang Z. D., Chen Y. N., Brem H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer. 1994 Jun 15;57(6):920–925. doi: 10.1002/ijc.2910570624. [DOI] [PubMed] [Google Scholar]
  53. Törnell J., Carlsson B., Pohjanen P., Wennbo H., Rymo L., Isaksson O. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):237–242. doi: 10.1016/0960-0760(92)90213-3. [DOI] [PubMed] [Google Scholar]
  54. Vennin P., Peyrat J. P., Bonneterre J., Louchez M. M., Harris A. G., Demaille A. Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res. 1989 Jan-Feb;9(1):153–155. [PubMed] [Google Scholar]
  55. Weckbecker G., Raulf F., Tolcsvai L., Bruns C. Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion. 1996;57 (Suppl 1):22–28. doi: 10.1159/000201388. [DOI] [PubMed] [Google Scholar]
  56. Weckbecker G., Tolcsvai L., Stolz B., Pollak M., Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. Cancer Res. 1994 Dec 15;54(24):6334–6337. [PubMed] [Google Scholar]
  57. Xu Y., Song J., Berelowitz M., Bruno J. F. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology. 1996 Dec;137(12):5634–5640. doi: 10.1210/endo.137.12.8940394. [DOI] [PubMed] [Google Scholar]
  58. van Eijck C. H., Krenning E. P., Bootsma A., Oei H. Y., van Pel R., Lindemans J., Jeekel J., Reubi J. C., Lamberts S. W. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet. 1994 Mar 12;343(8898):640–643. doi: 10.1016/s0140-6736(94)92637-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES